Valuation: Spatializer Audio Laboratories, Inc.

Market Cap 6.31M 5.41M 5.06M 4.62M 8.73M 602M 8.81M 59.65M 23.24M 303M 23.69M 23.18M 1B P/E 2024
-0.28x
P/E 2025 -0.1x
Enterprise Value 1.63M 1.4M 1.31M 1.2M 2.26M 156M 2.28M 15.44M 6.02M 78.51M 6.13M 6M 260M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -

Financials

2024 2025
Net sales - -
Net income -9.57M -8.2M -7.67M -7.02M -13.25M -913M -13.37M -90.5M -35.26M -460M -35.95M -35.17M -1.52B -8.77M -7.51M -7.03M -6.43M -12.14M -837M -12.25M -82.91M -32.3M -422M -32.93M -32.22M -1.4B
Net Debt -2.24M -1.92M -1.8M -1.64M -3.1M -214M -3.13M -21.18M -8.25M -108M -8.41M -8.23M -357M -4.68M -4.01M -3.75M -3.43M -6.47M -446M -6.53M -44.21M -17.22M -225M -17.56M -17.18M -745M
Logo Spatializer Audio Laboratories, Inc.
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians. The Company is advancing its pipeline of new-generation of naturally occurring and synthetic compounds. It is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.
Employees
-
Sector
-